Lipella Pharmaceuticals Faces Delisting Concerns

TL;DR

Lipella Pharma might get delisted, trading could be toast.

AI Summary

Lipella Pharmaceuticals Inc. filed an 8-K on August 23, 2024, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The earliest event reported was on August 21, 2024. The company is incorporated in Delaware and its principal executive office is located in Pittsburgh, PA.

Why It Matters

This filing indicates potential issues with Lipella Pharmaceuticals' continued listing on an exchange, which could significantly impact its stock trading and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a significant risk to investors.

Key Players & Entities

• Lipella Pharmaceuticals Inc. (company) — Registrant
• August 23, 2024 (date) — Filing Date
• August 21, 2024 (date) — Earliest Event Reported Date
• Delaware (jurisdiction) — State of Incorporation
• Pittsburgh, PA (location) — Principal Executive Office

FAQ

Key Financial Figures

• $0.0001 — registered Common Stock, par value $0.0001 per share LIPO The Nasdaq Capital M
• $2,500,000 — ket ("Nasdaq") to maintain a minimum of $2,500,000 in stockholders' equity for continued l
• $1,703,798 — ompany reported stockholders' equity of $1,703,798 in its Quarterly Report on Form 10-Q fo

Filing Documents

• g084405_8k.htm (8-K) — 36KB
• 0001753926-24-001473.txt ( ) — 209KB
• lipo-20240823.xsd (EX-101.SCH) — 3KB
• lipo-20240823_lab.xml (EX-101.LAB) — 33KB
• lipo-20240823_pre.xml (EX-101.PRE) — 22KB
• g084405_8k_htm.xml (XML) — 4KB

01

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 21, 2024, Lipella Pharmaceuticals Inc. (the "Company") received a letter from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC (the "Staff") stating that it was not in compliance with Rule 5550(b)(1) of The Nasdaq Stock Market LLC ("Rule 5550(b)(1)"), which requires companies listed on the Nasdaq Capital Market ("Nasdaq") to maintain a minimum of $2,500,000 in stockholders' equity for continued listing (the "Stockholders' Equity Requirement"). The Company reported stockholders' equity of $1,703,798 in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, which is below the $2,500,000 threshold required by the Stockholders' Equity Requirement. The Company is required to submit to the Staff a plan to regain compliance with the Stockholders' Equity Requirement for consideration by the Staff no later than October 7, 2024. The Company intends to timely submit a compliance plan for the Staff's review. If the Staff accepts the plan, the Staff may grant the Company an extension of up to 180 calendar days from August 21, 2024 (the "Extension Period") to evidence compliance with the Stockholders' Equity Requirement. If the Staff does not accept the Company's plan, the Company may request a hearing, at which hearing it would present its plan to a Nasdaq hearings panel and request the continued listing of its common stock, par value $0.0001 per share (the "Common Stock"), on Nasdaq pursuant to and pending the completion of such plan. During the pendency of the hearing process, the Common Stock would continue to be listed on Nasdaq. The Company anticipates regaining compliance with the Stockholders' Equity Requirement during the Extension Period. However, there can be no assurance that the Company will be able to satisfy the Stockholders' Equity Requirement, will otherwise be in compliance with other Nasdaq listing c

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 23, 2024 Lipella Pharmaceuticals Inc. By: /s/ Jonathan Kaufman Name: Jonathan Kaufman Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR